-
Apr 16, 2025, 06:40 AM
by
VieCure is making thousands of the most commonly used NCCN Chemotherapy Order Templates available on its Halo Intelligence Platform.
Full story
-
Apr 16, 2025, 01:00 AM
by
User Not Found
Bio-IT World | During the final plenary keynote of this year’s Bio-IT World Conference & Expo, we heard from Tris Dyson, Challenge Works, and Jeffrey Rothstein, Johns Hopkins University; Robert Green, Harvard Medical School; and Justin Scheer, Johnson & Johnson Innovative Medicine. They all gave presentations that highlighted artificial intelligence (AI) and machine learning’s (ML) ever-growing roles in research and healthcare, as well as the impact they have on the future of patient treatment, drug development, and more.
Full story
-
Apr 15, 2025, 06:35 AM
by
Oxford Nanopore Technologies announced the expansion of its Compatible Products Program. New participating companies include: 10x Genomics, Agilent Technologies, Asuragen, Day Zero Diagnostics, Hamilton Robotics, NEB, Opentrons, Pathosense, and Thermo Fisher Scientific.
Full story
-
Apr 15, 2025, 06:35 AM
by
The launch of a new mid-sized CDMO, Meribel Pharma Solutions, bringing together 10 manufacturing sites and 3 development centres across Europe. The team – including ex-Synerlab and Catalent leadership – aims to offer agile, high-quality solutions across OSD, sterile, and semi-solid manufacturing.
Built on a strong legacy, the company is filling a much-needed niche in the market with centres of excellence in lyophilisation, preservative-free multidose tech, and more.
Full story
-
Apr 15, 2025, 01:00 AM
by
User Not Found
Bio-IT World | At last week’s Venture, Innovation, and Partnering Summit at the Bio-IT World Conference & Expo, Derek Lowe, Director, Chemical Biology & Therapeutics at Novartis BioMedical Research, and John Keilty, venture partner at Third Rock Ventures, sat down for a candid conversation on the pharmaceutical industry and the current state of artificial intelligence and machine learning (AI/ML) in drug discovery.
Full story
-
Apr 14, 2025, 12:57 PM
by
● Membrane proteins synthesized and purified within 48 hours.
● Active membrane transporter, MsbA and integral membrane protein, ZMPSTE24 synthesized
Full story
-
Apr 11, 2025, 08:06 AM
by
Full story
-
Apr 11, 2025, 08:06 AM
by
EMAS Pharma has officially rebranded as Evestia Clinical, signaling a bold new chapter as a specialised Contract Research Organization (CRO) dedicated to oncology and rare disease clinical trials.
With the backing of Kester Capital and a leadership team with a proven track record, Evestia Clinical is set to redefine the clinical research landscape by delivering agile, expert-driven solutions to biotech innovators worldwide. With a rapidly growing demand for faster, more adaptive trials in complex therapeutic areas, this transformation comes at a critical time for the industry.
The new identity underscores the company’s commitment to accelerating life-changing therapies to market while strengthening its strategic partnerships with biotech firms globally.
Full story
-
Apr 11, 2025, 08:06 AM
by
Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health (MDGH), a not for profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most.
Full story
-
Apr 11, 2025, 08:06 AM
by
High Force Research, a leading UK-based provider of specialist chemical R&D and manufacturing services has just appointed Dr. Nathalie Huther as its first-ever Chief Commercial Officer following a recent management buyout.
This is a pivotal moment for the company, as it gears up to accelerate growth and deepen its presence in the pharmaceutical, biotech, and specialty chemicals markets. Nathalie brings 15+ years of commercial leadership experience across the chemical and life sciences sectors and will be steering High Force Research’s business development and market expansion strategy.
Full story
-
Apr 10, 2025, 08:44 AM
by
Cepheid and Oxford Nanopore Technologies announce new collaboration to develop an integrated sequencing workflow to advance infectious disease analysis.
Full story
-
Apr 10, 2025, 08:44 AM
by
News from Cellistic, which has launched its new Echo™-NK platform to support the production of off-the-shelf Natural Killer cell therapies.
The platform offers a cost-effective, GMP-compliant solution for scaling iPSC-derived NK cells, aimed at treating cancers and autoimmune diseases.
It also integrates Cellistic’s STAR-CRISPR and Pulse technologies to help speed up development, with several client projects already in progress.
Full story
-
Apr 10, 2025, 08:44 AM
by
Vaxess Technologies, Inc., a biotech company developing a novel microarray patch technology to transform home delivery of therapies, today announced it has received an additional $9 million in funding. Investors included RA Capital Management and Engine Ventures.
Full story
-
Apr 10, 2025, 01:00 AM
by
User Not Found
Bio-IT World | Scientists use prior knowledge to solve new problems, and a novel artificial intelligence (AI) system known as LLM4SD (Large Language Model 4 Scientific Discovery) can likewise synthesize knowledge from existing literature. But the method “goes beyond simply repeating information” by interpreting it and coming up with new hypotheses.
Full story
-
Apr 9, 2025, 08:08 AM
by
Our latest press release announces the launch of the RNome Disruptive Research Grant, a new funding opportunity designed to empower scientists exploring the complexities of RNA. We believe this development will be of significant interest to your audience, particularly those working in RNA research, genomics, molecular biology, and related fields.
The press release highlights our commitment to advancing RNA science through a competitive grant that will award five researchers $5,000 USD each, along with a one-on-one consultation with our scientific team.
Full story
-
Apr 9, 2025, 08:08 AM
by
Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today announced a significant expansion of its APAC distributor network. This development marks a key milestone in the Company’s global commercial strategy to meet growing demand for its next-generation single-cell analysis platforms.
Full story
-
Apr 9, 2025, 01:00 AM
by
User Not Found
Bio-IT World | At the opening plenary panel at last week’s Bio-IT World Conference & Expo, speakers from pharma, healthcare, and biotech took on the future of AI for pharma and healthcare. Abbie Celniker, Partner, Third Rock Ventures, moderated the conversation which included viewpoints from Per Greisen, President, BioMap; Sofia Guerra, Vice President, Bessemer Venture Partners; Subha Madhavan, Vice President and Head, AI/ML, Quantitative and Digital Sciences, Pfizer; and Sonya Makhni, MD, Medical Director, Mayo Clinic Platform.
Full story
-
Apr 8, 2025, 08:17 AM
by
Indivumed is proud to announce major milestones achieved, cementing its position as a leading oncology R&D company.
Full story
-
Apr 8, 2025, 01:00 AM
by
User Not Found
Bio-IT World| Oral drugs are considered an ideal delivery method for medications because of their noninvasive nature, but they face the challenge of passing through the acidic environment of the upper gastrointestinal (GI) tract. Specifically, the stomach acts as a barrier to anything biological, including oral drugs with biologic content. To overcome this obstacle, a team of researchers at Virginia Tech engineered microbes called bacteriophages, or phages, to infect and reprogram gut bacterial cells to produce and release a sustained flow of a protein-based drug.
Full story
-
Apr 4, 2025, 11:52 AM
by
User Not Found
Bio-IT World | Yesterday in Boston the Bio-IT World community at the Bio-IT World Conference & Expo honored four new products in the annual Bio-IT World Best of Show competition. New products from Boulder BioComputing, Dantech Corp, The Hyve, and Velsera took top honors.
Full story